Adverse Event Reviews: FDA Needs To Boost ‘Accuracy And Efficiency’
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency seeks academic institutions and commercial organizations with tools that can conduct automated analysis of case reports from FAERS data.
You may also be interested in...
Adverse Event Reports Rising, FDA Staffing Levels Not Keeping Pace
Adverse event reports per year have quadrupled over the last decade, and FDA expects the reports to retain their importance even as new technology helps with drug safety monitoring.
Drug Safety Business: Start-Up With AERS Filter Eyes Bisphosphonate Events
A small start-up company has developed a technique to filter the data in FDA’s Adverse Events Reporting System (AERS) database, which it says provides a more accurate analysis of adverse event reports.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.